Principia Biopharma

General Information


We are a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology. Our proprietary Tailored Covalency® platform enables us to design and develop reversible covalent and irreversible covalent, small molecule inhibitors with potencies and selectivities that we believe will rival those of injectable biologics, yet maintain the convenience of a pill.

Employees: 47
Founded: 2008
Contact Information
Address 400 East Jamie Court, Suite 302, South San Francisco, CA 94080, US
Phone Number (650) 416-7700
Web Address
View Prospectus: Principia Biopharma
Financial Information
Market Cap $363.7mil
Revenues $29.3 mil (last 12 months)
Net Income $-7.8 mil (last 12 months)
IPO Profile
Symbol PRNB
Exchange NASDAQ
Shares (millions): 6.3
Price range $17.00 - $17.00
Est. $ Volume $106.3 mil
Manager / Joint Managers BofA Merrill Lynch/ Leerink Partners/ Wells Fargo Securities
CO-Managers Baird
Expected To Trade: 9/14/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change